Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.
Publication
, Conference
Friedberg, JW; Younes, A; Fisher, DC; Gordon, LI; Moore, JO; Czuczman, MS; Miller, TP; Stiff, PJ; Cheson, BD; Forero-Torres, A; McKinney, B ...
Published in: BLOOD
November 16, 2008
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2008
Volume
112
Issue
11
Start / End Page
369 / 370
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
50th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Friedberg, J. W., Younes, A., Fisher, D. C., Gordon, L. I., Moore, J. O., Czuczman, M. S., … Leonard, J. P. (2008). Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial. In BLOOD (Vol. 112, pp. 369–370). San Francisco, CA: AMER SOC HEMATOLOGY.
Friedberg, Jonathan W., Anas Younes, David C. Fisher, Leo I. Gordon, Joseph O. Moore, Myron S. Czuczman, Thomas P. Miller, et al. “Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.” In BLOOD, 112:369–70. AMER SOC HEMATOLOGY, 2008.
Friedberg JW, Younes A, Fisher DC, Gordon LI, Moore JO, Czuczman MS, et al. Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial. In: BLOOD. AMER SOC HEMATOLOGY; 2008. p. 369–70.
Friedberg, Jonathan W., et al. “Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.” BLOOD, vol. 112, no. 11, AMER SOC HEMATOLOGY, 2008, pp. 369–70.
Friedberg JW, Younes A, Fisher DC, Gordon LI, Moore JO, Czuczman MS, Miller TP, Stiff PJ, Cheson BD, Forero-Torres A, McKinney B, Leonard JP. Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial. BLOOD. AMER SOC HEMATOLOGY; 2008. p. 369–370.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2008
Volume
112
Issue
11
Start / End Page
369 / 370
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
50th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology